Mesothelioma can strike at any time, but it most commonly affects those in their 70s, with cases continuing well into the 2030s. The time from exposure to diagnosis can be up to 60 years. This week, we explore treatment options for pleural mesothelioma, including ipilimumab and nivolumab, and consider whether chemotherapy and bevacizumab work for mesothelioma as well. The MAPS trial was published in 2016, while Checkmate was published in 2022.

Studies discussed in this episode:

MAPS

Checkmate 743

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.

Hosted on Acast. See acast.com/privacy for more information.